BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12059866)

  • 21. A prospective study of the effects of prolonged timolol therapy on alpha- and beta-adrenoceptor and angiotensin II receptor mediated responses in normal subjects.
    Ferro A; Hall JA; Dickerson JE; Brown MJ
    Br J Clin Pharmacol; 1997 Mar; 43(3):301-8. PubMed ID: 9088585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
    Goñi FJ;
    Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of brimonidine tartrate on ocular hemodynamics in healthy volunteers.
    Jonescu-Cuypers CP; Harris A; Ishii Y; Kagemann L; Gazozi HJ; Rotenstreich Y; Chung HS; Martin B
    J Ocul Pharmacol Ther; 2001 Jun; 17(3):199-205. PubMed ID: 11436940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for visual field progression in the low-pressure glaucoma treatment study.
    De Moraes CG; Liebmann JM; Greenfield DS; Gardiner SK; Ritch R; Krupin T;
    Am J Ophthalmol; 2012 Oct; 154(4):702-11. PubMed ID: 22835512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
    Krupin T; Liebmann JM; Greenfield DS; Ritch R; Gardiner S;
    Am J Ophthalmol; 2011 Apr; 151(4):671-81. PubMed ID: 21257146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily.
    Stewart WC; Stewart JA; Day D; Sharpe ED
    Acta Ophthalmol Scand; 2003 Jun; 81(3):242-6. PubMed ID: 12780402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
    Serle JB
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S39-47. PubMed ID: 8970248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1% and Timolol Maleate 0.5% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma.
    Mizoue S; Nitta K; Shirakashi M; Nitta A; Yamabayashi S; Kimura T; Ueda T; Takeda R; Matsumoto S; Yoshikawa K
    Adv Ther; 2017 Jun; 34(6):1438-1448. PubMed ID: 28508306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide.
    Hommer A; Kapik B; Shams N;
    Br J Ophthalmol; 2003 May; 87(5):592-8. PubMed ID: 12714402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension.
    WoldeMussie E; Ruiz G; Wijono M; Wheeler LA
    Invest Ophthalmol Vis Sci; 2001 Nov; 42(12):2849-55. PubMed ID: 11687528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closure.
    Aung T; Oen FT; Wong HT; Chan YH; Khoo BK; Liu YP; Ho CL; See J; Thean LH; Viswanathan AC; Seah SK; Chew PT
    Br J Ophthalmol; 2004 Jan; 88(1):88-94. PubMed ID: 14693782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure.
    Arcieri ES; Arcieri RS; Pereira AC; Andreo EG; Finotti IG; Sá Filho WF
    Curr Med Res Opin; 2007 Apr; 23(4):683-9. PubMed ID: 17407624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antianginal efficacy and improved exercise performance with timolol. Twice-daily beta blockade in ischemic heart disease.
    Harris FJ; Low RI; Paumer L; Amsterdam EA; Mason DT
    Am J Cardiol; 1983 Jan; 51(1):13-8. PubMed ID: 6129794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.
    Frampton JE
    Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The 24-Hour Effects of Brinzolamide/Brimonidine Fixed Combination and Timolol on Intraocular Pressure and Ocular Perfusion Pressure.
    Seibold LK; DeWitt PE; Kroehl ME; Kahook MY
    J Ocul Pharmacol Ther; 2017 Apr; 33(3):161-169. PubMed ID: 28129020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel.
    Uusitalo H; Niño J; Tahvanainen K; Turjanmaa V; Ropo A; Tuominen J; Kähönen M
    Acta Ophthalmol Scand; 2005 Dec; 83(6):723-8. PubMed ID: 16396651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic beta-blockade with once daily Betimol or Timoptic-XE.
    Stewart WC; Cate EA; Stewart JA
    J Ocul Pharmacol Ther; 1999 Jun; 15(3):225-31. PubMed ID: 10385131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.